Drug Trial Radar · NCT06863662
Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm
Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
136
Actual
Start
Sep 18, 2024
Primary completion
Sep 26, 2025
Study completion Dec 1, 2025
Sponsor
- Lead sponsor
- Laboratorios Silanes S.A. de C.V.Industry
- Sponsor type
- Industry
- First posted
- Mar 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, longitudinal, multicenter, randomized, double-blind clinical trial. The aim of the study is to evaluate the efficacy and safety of a fixed-dose combination of etoricoxib and tizanidine compared to etoricoxib alone in patients with acute low back pain associated with muscle spasms.
Conditions
- Acute Low-back Pain
- Muscle Spasm; Back Pain
Interventions
Etoricoxib + Tizanidine fixed doseDrug
One sachet with 120 mg / 4 mg, dissolved in 100 mL of water
Etoricoxib fixed doseDrug
One sachet with 120 mg, dissolved in 100 mL of water
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of the percentage change in pain intensity, as measured by the Visual Analog Scale (VAS), on Days 1, 3, 5, and 7 of follow-up relative to baseline, within each treatment group.Time frame: 7 days
- Number of participants reporting treatment-related adverse events, as documented in the patient diary.Time frame: 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Laboratorio Silanes, S.A. de C.V.
Mexico City, Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.